Skip to main content
    E

    Enliven Therapeutics Inc. (ELVN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $46.85
    -0.77 (-1.62%)

    Market Cap: $3.50B

    Last updated: Nov 17, 2026 at 4:15 PM ET

    Enliven Therapeutics Inc. (ELVN) Stock Chart

    Updated Nov 17, 2026. Prices from end-of-day market data; valuation figures from company filings.

    Enliven Therapeutics (ELVN) has a latest price of $46.85 on Nov 17, 2026, 24.8% below its 52-week high of $62.32. Its price rose 112.3% over the past 12 months. The month-end price rose 207.3% over the 5 years through Oct 2026, a compound annual rate of 25.2%.

    Price Chart

    From Mar 2020 to Oct 2026, its highest month-end close was $133.96 in May 2020 and its lowest $4.68 in Jul 2022, adjusted for splits.

    Month-end closes, adjusted for splits. Dividends are not included.

    Chart ELVN with Advanced Charting

    Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ELVN.

    Free with a GNG account. No credit card.

    Price Performance

    Over the past 3 months the price fell 21.1%, and over 6 months it rose 16.6%. The month-end price rose 257.1% over the 3 years through Oct 2026, a compound annual rate of 52.9%.

    PeriodChange
    1 month+21.1%
    3 months-21.1%
    6 months+16.6%
    12 months+112.3%
    12 months, with dividends+112.3%
    Price change over each period. Dividends are not included unless the row says so.
    PeriodChangePer year
    3 years+257.1%+52.9%
    5 years+207.3%+25.2%
    From month-end closes through Oct 2026. Per year is the compound annual rate.

    Price by Year

    Its best calendar year was 2022, when the price rose 81.8%, and its weakest was 2021, when it fell 89.8%.

    YearCloseChange
    2026 through Oct 2026$44.25+187.3%
    2025$15.40-31.6%
    2024$22.50+62.6%
    2023$13.84-15.4%
    2022$16.36+81.8%
    2021$9.00-89.8%
    Each year ends at its December month-end close, adjusted for splits.

    Trading Range

    The price is 2.0% above its 50-day average of $45.95 and 6.4% above its 200-day average of $44.03.

    MeasureValuePrice vs
    Latest price (Nov 17, 2026)$46.85
    52-week high$62.32-24.8%
    52-week low$14.79+216.8%
    50-day average$45.95+2.0%
    200-day average$44.03+6.4%
    Moving averages of daily closes. The last column compares the price with each level.

    Price Risk

    Over 3 years, its largest fall from a peak was 49.5%.

    MeasureValue
    1-year beta1.12
    Largest fall, 1 year-39.0%
    Largest fall, 3 years-49.5%
    Beta against the S&P 500 over one year. A fall is measured from a peak to the low after it.

    Advanced Charting Features

    Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.

    • Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
    • Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
    • Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
    • Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.

    Frequently Asked Questions About ELVN

    What is ELVN's 1-year price change?

    Enliven Therapeutics's price rose 112.3% over the past 12 months. With dividends included, the 12-month total return was 112.3%.

    What is ELVN's 5-year price change?

    Enliven Therapeutics's month-end price rose 207.3% over the 5 years through Oct 2026, a compound annual rate of 25.2%. These figures leave out dividends.

    What is ELVN's 52-week high and low?

    Enliven Therapeutics's 52-week high is $62.32 and its 52-week low is $14.79. Its latest price of $46.85 on Nov 17, 2026 is 24.8% below the high.

    What is ELVN's beta?

    Enliven Therapeutics's 1-year beta against the S&P 500 is 1.12, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 39.0%.

    Is the ELVN chart free?

    Yes. Advanced Charting for ELVN is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.